New antivirals for the treatment of chronic hepatitis B. (3rd July 2017)

• Record Type: Journal Article
• Authors: Soriano, Vincent; Barreiro, Pablo; Benitez, Laura; Peña, Jose M.; de Mendoza, Carmen
• Is Part Of: Expert opinion on investigational drugs. Volume 26:Number 7(2017)
• Page Start: 843
• Page End: 851
• Publication Date: 2017-07-03
• Subjects: Hepatitis B -- capsid inhibitors -- cccDNA -- entry inhibitors -- immunomodulators -- RNAi -- TAF -- novel therapy -- nucleos(t)ide analogues -- polymerase inhibitors -- therapeutic vaccines -- TLR7 agonist; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2017.1333105
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. There is renewed enthusiasm on HBV drug discovery following recent successes with antivirals for hepatitis C and immunotherapies for some cancers. Areas covered : New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription. Alongside these antivirals, agents that enhance anti-HBV specific immune responses are being tested, including TLR agonists, checkpoint inhibitors and therapeutic vaccines. Expert opinion : The achievement of a 'functional cure' for chronic HBV infection, with sustained HBsAg clearance and undetectable viremia once medications are stopped, represents the next step in the pace towards HBV elimination. Hopefully, the combination of new drugs that eliminate or functionally inactivate the genomic HBV reservoirs (cccDNA and integrated HBV-DNA) along with agents that enhance or activate immune responses against HBV will lead to a 'definitive cure' for chronic HBV infection.